Collaboration to focus on enabling clinicians to open clinical trials at the point of care.
Flatiron Health announced that it will be partnering with Penn Medicine to bring its Flatiron Assist to Penn’s Abramson Cancer Center (ACC). The project aims to further enable clinicians at ACC to determine and promote site-preferred pathways and open clinical trials at the point of care alongside the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).
“At Flatiron, we are committed to elevating clinical care and unlocking the power of patient data, so every person’s experience can inform and improve outcomes for future patients. Partnering with Penn Medicine’s Abramson Cancer Center, a market-leading cancer care provider and a pioneer of digital innovation in healthcare, enables us to use data for good and reimagine the infrastructure of cancer care,” said Julia Morton, SVP, GM, Flatiron HC. “We are looking forward to working together to accelerate the delivery of more standardized, efficient, and effective cancer care across the entire health system.”
Reference: Flatiron Health Launches New Strategic Collaboration to Advance Health Insights and Equity of Cancer Care. BusiessWire. October 23, 2023. Accessed October 23, 2023. https://www.businesswire.com/news/home/20231023565932/en/Flatiron-Health-Launches-New-Strategic-Collaboration-to-Advance-Health-Insights-and-Equity-of-Cancer-Care
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.